NCT01345851

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Active, enrolled NA Last updated 25 February 2026

What this trial tests

NA trial testing hypofractionated radiation therapy in Adenocarcinoma of the Lung in 29 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 March 2011

Primary endpoint
31 January 2027

31 January 2028

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	23 March 2011
Primary completion	31 January 2027
Estimated completion	31 January 2028
Sites	1 location across United States

Drugs / interventions tested

• hypofractionated radiation therapy — full drug profile →
• laboratory biomarker analysis — full drug profile →
• image-guided radiation therapy
• carboplatin (Carboplatin) — full drug profile →
• paclitaxel — full drug profile →
• stereotactic body radiation therapy

Conditions studied

• Adenocarcinoma of the Lung — all drugs for Adenocarcinoma of the Lung →
• Adenosquamous Cell Lung Cancer — all drugs for Adenosquamous Cell Lung Cancer →
• Large Cell Lung Cancer — all drugs for Large Cell Lung Cancer →
• Recurrent Non-small Cell Lung Cancer — all drugs for Recurrent Non-small Cell Lung Cancer →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Adenocarcinoma of the Lung or Adenosquamous Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given together with hypofractionated RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. RT uses high energy x-rays to kill tumor cells. Hypofractionated RT may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RT together with combination chemotherapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. The evolving toxicity profile of SBRT for lung cancer.
   Thompson M, Rosenzweig KE. · · 2019 · cited 45× · PMID 30788234 · DOI 10.21037/tlcr.2018.10.06
2. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
   Wu TC, Luterstein E, Neilsen BK, Goldman JW, et al · · 2024 · cited 19× · PMID 38206614 · DOI 10.1001/jamaoncol.2023.6033
3. Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends.
   Maciejczyk A, Skrzypczyńska I, Janiszewska M. · · 2014 · cited 17× · PMID 25337407 · DOI 10.1016/j.rpor.2014.04.012
4. Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer.
   Alcibar OL, Nadal E, Romero Palomar I, Navarro-Martin A. · · 2021 · cited 10× · PMID 33569334 · DOI 10.21037/tlcr-2020-nsclc-04
5. Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions.
   Chehade S, Palma DA. · · 2015 · cited 6× · PMID 26696779 · DOI 10.1016/j.rpor.2014.11.007